Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganmiao Kangning granules is a traditional Chinese medicine (TCM) candidate developed by the Beijing Beiyi Modern Traditional Chinese Medicine Technology Development Center for the treatment of the common cold, specifically the wind-heat pattern. It is a botanical formulation designed to alleviate symptoms such as fever, sore throat, and nasal congestion. The drug underwent a randomized, double-blind, placebo-controlled Phase 2 clinical trial in China to evaluate its safety and efficacy across different dosage levels in adult patients. As a granule formulation, it is intended for oral administration and follows traditional principles of clearing heat and expelling wind.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganmiao Kangning granules.